Case number 1:21-cv-01794
Novartis Pharmaceuticals Corporation v. Torrent Pharma Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Aug 30, 2024 | 169 | REDACTED VERSION of 168 Joint Motion to Vacate Judgment as to Torrent Pursuant to Federal Rules of Civil Procedure 62.1 and 60(b), by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 9/3/2024 (nms). (Entered: 08/30/2024) (5) |
| Aug 23, 2024 | 168 | [SEALED] Joint Motion to Vacate Judgment as to Torrent Pursuant to Federal Rules of Civil Procedure 62.1 and 60(b) - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A)(Joyce, Alexandra) Modified on 8/23/2024 (nms). (Entered: 08/23/2024) (0) |
| Jul 18, 2024 | 167 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,058,667. (Attachments: # 1 Consent Judgment (redacted version))(nms) (Entered: 07/18/2024) (0) |
| Jul 12, 2024 | 165 | REDACTED VERSION of 163 Proposed Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/14/2024 (nms). (Entered: 07/12/2024) (4) |
| Jul 12, 2024 | 166 | REDACTED VERSION of 164 Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/14/2024 (nms). (Entered: 07/12/2024) (4) |
| Jul 8, 2024 | 164 | [SEALED] Consent Judgment and Order of Injunction. Signed by Judge Richard G. Andrews on 7/8/2024.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:21-cv-01794-RGA(nms) (Entered: 07/08/2024) (0) |
| Jul 5, 2024 | 163 | [SEALED] PROPOSED Consent Judgment and Order of Injunction, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/7/2024 (nms). (Entered: 07/05/2024) (0) |
| Jun 20, 2024 | 161 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding electronic version of Plaintiff's Sur-Reply Post-Trial Brief on the Validity of U.S. Patent No. 11,058,667. (Silver, Daniel) Modified on 6/20/2024 (nms). (Entered: 06/20/2024) (1) |
| Jun 20, 2024 | 162 | Sur-Surreply Post-Trial Brief on the invalidity of U.S. Patent No. 11,058,667, by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Taylor, Daniel) Modified on 6/20/2024 (nms). (Entered: 06/20/2024) (3) |
| Jun 18, 2024 | 159 | SO ORDERED Granting (D.I. 158 in 21-cv-1794-RGA; D.I. 166 in 21-cv-1760-RGA; D.I. 1386 in 20-md-2930-RGA) Stipulation and Proposed Order Regarding Additional Post-Trial Briefing with Respect to U.S. Patent No. 11,058,667. Signed by Judge Richard G. Andrews on 6/18/2024. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01760-RGA, 1:21-cv-01794-RGA(nms) (Entered: 06/18/2024) (8) |
| Jun 18, 2024 | 160 | Sur-Reply Post-Trial Brief on the Validity of U.S. Patent No. 11,058,667, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/18/2024 (nms). (Entered: 06/18/2024) (4) |
| Jun 14, 2024 | 158 | STIPULATION and [Proposed] Order Regarding Additional Post-Trial Briefing with Respect to U.S. Patent No. 11,058,667, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A)(Joyce, Alexandra) Modified on 6/17/2024 (nms). (Entered: 06/14/2024) (0) |
| Jun 12, 2024 | 157 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding submission of electrnic version of reply post-trial brief. (Silver, Daniel) Modified on 6/12/2024 (nms). (Entered: 06/12/2024) (1) |
| Jun 7, 2024 | 155 | POST-Trial Reply Brief on Invalidity of the '918 and '667 Patents, by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Taylor, Daniel) Modified on 6/9/2024 (nms). (Entered: 06/07/2024) (25) |
| Jun 7, 2024 | 156 | POST-Trial Brief on Hetero's and Torrent's Infringement of U.S. Patent No. 11,058,667, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/9/2024 (nms). (Entered: 06/07/2024) (21) |
| May 16, 2024 | 154 | SO ORDERED Granting (D.I. 257 in 21-cv-1330-RGA; D.I. 160 in 21-cv-1760-RGA; D.I. 153 in 21-cv-1794-RGA; D.I. 1369 in 20-md-2930-RGA) STIPULATION and Proposed Order to Extend Time to submit Post-Trial Reply Briefs to June 7, 2024, and hyperlinked briefs to June 12, 2024. Signed by Judge Richard G. Andrews on 5/16/2024. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:21-cv-01760-RGA, 1:21-cv-01794-RGA(nms) (Entered: 05/16/2024) (3) |
| May 15, 2024 | 153 | STIPULATION and Proposed Order to Extend Time - filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,. (Taylor, Daniel) Modified on 5/15/2024 (nms). (Entered: 05/15/2024) (3) |
| May 10, 2024 | 151 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding hyperlinked post-trial documents. (Silver, Daniel) Modified on 5/10/2024 (nms). (Entered: 05/10/2024) (1) |
| May 10, 2024 | 152 | Letter to The Honorable Richard G. Andrews, from Daniel A. Taylor, regarding hyperlinked post-trial documents. (Taylor, Daniel) Modified on 5/10/2024 (nms). (Entered: 05/10/2024) (1) |
| May 3, 2024 | 147 | POST TRIAL Answering Brief on the Validity of the '667 and '918 Patents, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/3/2024 (nms). (Entered: 05/03/2024) (30) |
| May 3, 2024 | 148 | Proposed Findings of Fact by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 05/03/2024) (30) |
| May 3, 2024 | 149 | POST TRIAL Answering Brief on Noninfringement of the '667 Patent, by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd.. (Taylor, Daniel) Modified on 5/3/2024 (nms). (Entered: 05/03/2024) (30) |
| May 3, 2024 | 150 | Proposed Findings of Fact by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd.. (Taylor, Daniel) Modified on 5/3/2024 (nms). (Entered: 05/03/2024) (30) |
| Apr 22, 2024 | 145 | Amended Proposed Findings of Fact on Hetero's and Trorrent's Infringement of U.S. Patent No. 11,058,667, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 4/22/2024 (nms). (Entered: 04/22/2024) (30) |
| Apr 22, 2024 | 146 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding corrected hyperlinked post-trial briefs. (Silver, Daniel) Modified on 4/22/2024 (nms). (Entered: 04/22/2024) (1) |
| Apr 4, 2024 | 140 | Official Transcript of Bench Trial held on 2/12/24 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/25/2024. Redacted Transcript Deadline set for 5/6/2024. Release of Transcript Restriction set for 7/3/2024. (Triozzi, Heather) (Main Document 140 replaced on 4/17/2024) (nms). (Entered: 04/04/2024) (263) |
| Apr 4, 2024 | 141 | Official Transcript of Bench Trial held on 2/13/24 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/25/2024. Redacted Transcript Deadline set for 5/6/2024. Release of Transcript Restriction set for 7/3/2024. (Triozzi, Heather) (Main Document 141 replaced on 4/17/2024) (nms). (Entered: 04/04/2024) (286) |
| Apr 4, 2024 | 142 | Official Transcript of Bench Trial held on 2/14/24 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/25/2024. Redacted Transcript Deadline set for 5/6/2024. Release of Transcript Restriction set for 7/3/2024. (Triozzi, Heather) (Main Document 142 replaced on 4/17/2024) (nms). (Entered: 04/04/2024) (236) |
| Apr 4, 2024 | 143 | Official Transcript of Bench Trial held on 2/15/24 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/25/2024. Redacted Transcript Deadline set for 5/6/2024. Release of Transcript Restriction set for 7/3/2024. (Triozzi, Heather) (Main Document 143 replaced on 4/17/2024) (nms). (Entered: 04/04/2024) (89) |
| Apr 4, 2024 | 144 | Official Transcript of Bench Trial held on 2/16/24 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/25/2024. Redacted Transcript Deadline set for 5/6/2024. Release of Transcript Restriction set for 7/3/2024. (Triozzi, Heather) (Main Document 144 replaced on 4/17/2024) (nms). (Entered: 04/04/2024) (82) |
| Apr 3, 2024 | 138 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding electronic versions of post-trial documents. (Silver, Daniel) Modified on 4/3/2024 (nms). (Entered: 04/03/2024) (1) |
| Apr 3, 2024 | 139 | Letter to The Honorable Richard G. Andrews, from Daniel A. Taylor, regarding electronic versions of post-trial documents. (Taylor, Daniel) Modified on 4/4/2024 (nms). (Entered: 04/03/2024) (1) |
| Apr 2, 2024 | 137 | NOTICE of Lodging of Defendants' Trial Demonstrative Exhibits used at the Trial held from February 12, 2024 to February 16, 2024 by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Torrent Pharmaceuticals Ltd., Hetero USA Inc., (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Taylor, Daniel) (Entered: 04/02/2024) (0) |
| Mar 27, 2024 | 133 | POST-Trial Brief regarding Hetero's and Torrent's Infringement of U.S. Patent No. 11,058,667, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 3/27/2024 (nms). (Entered: 03/27/2024) (30) |
| Mar 27, 2024 | 134 | Proposed Findings of Fact by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 03/27/2024) (30) |
| Mar 27, 2024 | 135 | POST-Trial Brief regarding Invalidity of the '918 and '667 Patents, by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,. (Taylor, Daniel) Modified on 3/27/2024 (nms). (Main Document 135 replaced on 5/22/2024) (nms). (Entered: 03/27/2024) (30) |
| Mar 27, 2024 | 136 | Proposed Findings of Fact by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,. (Taylor, Daniel) (Entered: 03/27/2024) (30) |
| Feb 28, 2024 | 131 | Exhibit List for Bench Trial held 2/12/2024 - 2/16/2024. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:21-cv-01760-RGA, 1:21-cv-01794-RGA. (lah) (Entered: 02/28/2024) (19) |
| Feb 28, 2024 | 132 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., enclosing Joint Trial Exhibits and Plaintiff's Exhibits. (Silver, Daniel) Modified on 2/29/2024 (nms). (Entered: 02/28/2024) (1) |
| Feb 21, 2024 | 129 | ORAL ORDER: The post-trial briefing schedule and limits submitted on 2/20/2024 (D.I. 128 in 21-cv-1794-RGA; D.I. 1271 in 20-md-2930-RGA; D.I. 237 in 21-cv-1330-RGA; D.I. 135 in 21-cv-1760-RGA) is APPROVED. Ordered by Judge Richard G. Andrews on 2/21/2024. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:21-cv-01760-RGA, 1:21-cv-01794-RGA(nms) (Entered: 02/21/2024) (0) |
| Feb 21, 2024 | 130 | REDACTED VERSION of 115 Proposed Pretrial Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 2/21/2024 (nms). (Entered: 02/21/2024) (30) |
| Feb 20, 2024 | 128 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding post-trial briefing. (Silver, Daniel) Modified on 2/21/2024 (nms). (Entered: 02/20/2024) (1) |
| Feb 9, 2024 | 126 | MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) (Entered: 02/09/2024) (3) |
| Feb 9, 2024 | 127 | ORAL ORDER: The Motion for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices (D.I. 132 in 21-cv-1760-RGA; D.I. 126 in 21-cv-1794-RGA; D.I. 1264 in 20-md-2930-RGA; D.I. 234 in 21-cv-1330-RGA) is DENIED. Ordered by Judge Richard G. Andrews on 2/9/2024. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:21-cv-01760-RGA, 1:21-cv-01794-RGA(nms) (Entered: 02/09/2024) (0) |
| Feb 8, 2024 | 122 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding experts curriculum vitae. (Attachments: # 1 Dr. Stuart Katz, # 2 Dr. Alexander M. Klibanov, # 3 Dr. Adam J. Matzger, # 4 Dr. Aeri Park, # 5 Dr. Francis Spinale, # 6 Dr. David R. Taft, # 7 Dr. Bernhardt Trout)(Silver, Daniel) Modified on 2/8/2024 (nms). (Entered: 02/08/2024) (0) |
| Feb 8, 2024 | 123 | Letter to The Honorable Richard G. Andrews, from Daniel A. Taylor, regarding experts' curriculum vitae. (Attachments: # 1 Dr. David A. Atwood, # 2 Dr. Jonathan W. Steed, # 3 Dan James Fintel, M.D.)(Taylor, Daniel) Modified on 2/8/2024 (nms). (Entered: 02/08/2024) (0) |
| Feb 8, 2024 | 124 | Unopposed Motion for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Proposed Order)(Silver, Daniel) Modified on 2/8/2024 (nms). (Entered: 02/08/2024) (0) |
| Feb 8, 2024 | 125 | ORDER Granting (D.I. 124 in 21-cv-1794-RGA; D.I. 128 in 21-cv-1760-RGA; D.I. 229 in 21-cv-1330-RGA; D.I. 1258 in 20-md-2930-RGA) Unopposed Motion for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices. Signed by Judge Richard G. Andrews on 2/8/2024. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:21-cv-01760-RGA, 1:21-cv-01794-RGA(nms) (Entered: 02/08/2024) (2) |
| Feb 7, 2024 | 121 | ORDER AFTER PRETRIAL CONFERENCE: The Proposed Pretrial Order (D.I. 1241) is ADOPTED, as modified by any discussion a the pretrial conference. A bench trial will begin on 2/12/2024, at 9:15 a.m. (see Order for further details). Signed by Judge Richard G. Andrews on 2/7/2024. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01760-RGA, 1:21-cv-01794-RGA(nms) (Entered: 02/07/2024) (2) |
| Feb 5, 2024 | 120 | STIPULATION and Proposed Order to Extend Time to file redacted versions of the Joint Proposed Pretrial Order, Defendants' Motion in Limine, and Novartis's Motion in Limine to February 21, 2024 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 2/6/2024 (nms). (Entered: 02/05/2024) (3) |
| Feb 1, 2024 | 119 | ORAL ORDER: The Parties are requested to provide the Court at the pretrial conference two copies each of the Park, Steed, and Atwood Reply Reports, the Park and Trout Sur-Reply Reports, the Steed and Atwood Sur-sur-Reply Reports, the Park Sur-sur-sur Reply Report, and the Steed Sur-sur-sur-sur-Reply Report. Ordered by Judge Richard G. Andrews on 2/1/2024. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:21-cv-01760-RGA, 1:21-cv-01794-RGA(nms) (Entered: 02/01/2024) (0) |
| Jan 30, 2024 | 116 | Letter to The Honorable Richard G. Andrews, from Daniel A. Taylor, responding to Plaintiff's letter dated 1/29/2024. (Taylor, Daniel) Modified on 1/30/2024 (nms). (Entered: 01/30/2024) (2) |
| Jan 30, 2024 | 117 | Joint Motion for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Proposed Order)(Joyce, Alexandra) Modified on 1/30/2024 (nms). (Entered: 01/30/2024) (0) |
| Jan 30, 2024 | 118 | SO ORDERED Granting (D.I. 1247 in 20-md-2930-RGA; D.I. 117 in 21-cv-1794-RGA; D.I. 120 in 21-cv-1760-RGA; D.I. 221 in 21-cv-1330-RGA) Joint Motion for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices. Signed by Judge Richard G. Andrews on 1/30/2024. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:21-cv-01760-RGA, 1:21-cv-01794-RGA(nms) (Entered: 01/30/2024) (4) |
| Jan 29, 2024 | 115 | [SEALED] Proposed Pretrial Order by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1A, # 2 Exhibit 1B, # 3 Exhibit 2A, # 4 Exhibit 2B, # 5 Exhibit 3A, # 6 Exhibit 3B, # 7 Exhibit 4A, # 8 Exhibit 4B, # 9 Exhibit 5A, # 10 Exhibit 5B, # 11 Exhibit 6A, # 12 Exhibit 6B, # 13 Exhibit 7A, # 14 Exhibit 7B, # 15 Exhibit 8A, # 16 Exhibit 8B, # 17 Exhibit 9A, # 18 Exhibit 9B, # 19 Exhibit 10A, # 20 Exhibit 10B, # 21 Exhibit 11A, # 22 Exhibit 11B, # 23 Exhibit 12A, # 24 Exhibit 12B)(Silver, Daniel) (Entered: 01/29/2024) (0) |
| Dec 18, 2023 | 114 | Joint letter to The Honorable Richard G. Andrews, from Daniel A. Taylor, regarding trials for the '667 & '918 patents. (Taylor, Daniel) Modified on 12/19/2023 (nms). (Entered: 12/18/2023) (3) |
| Nov 27, 2023 | 113 | SO ORDERED Granting (D.I. 112 in 21-cv-1794-RGA; D.I. 1205 in 20-md-2930-RGA) Stipulation With Respect to Authenticity and Admissibility of Documents. Signed by Judge Richard G. Andrews on 11/27/2023. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01794-RGA(nms) (Entered: 11/27/2023) (4) |
| Nov 21, 2023 | 112 | STIPULATION with Respect to Authenticity and Admissibility of Documents by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 11/21/2023) (4) |
| Nov 20, 2023 | 111 | NOTICE OF SERVICE of Sur-Reply Expert Report of Stuart D. Katz Regarding Validity of U.S. Patent No. 11,058,667 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 11/20/2023) (4) |
| Nov 6, 2023 | 109 | NOTICE OF SERVICE of Reply Expert Report of Dan Fintel, M.D. on The Invalidity of U.S. Patent No. 11,058,667 [Highly Confidential - Outside Attorneys' Eyes Only] (also filed on behalf of the Hetero and Torrent Defendants) filed by Mylan Pharmaceuticals Inc..(Palapura, Bindu) (Entered: 11/06/2023) (3) |
| Nov 6, 2023 | 110 | NOTICE OF SERVICE of (1) Reply Expert Report of Adam J. Matzger, Ph.D. on Infringement of U.S. Patent No. 11,058,667 by Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III, Mylan Pharmaceuticals Inc., Torrent Pharma Inc., and Torrent Pharmaceuticals Ltd., (2) Reply Expert Report of Alexander M. Klibanov, Ph.D., on the Infringement of the '667 Patent, and (3) Reply Expert Report of Dr. Francis G. Spinale on the Infringement of the '667 Patent filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 11/06/2023) (4) |
| Oct 25, 2023 | 108 | NOTICE OF SERVICE of Novartis's Objections and Responses to Defendants' Supplemental Notice of Deposition to Plaintiff Novartis Pharmaceuticals Corporation Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 10/25/2023) (4) |
| Oct 19, 2023 | 106 | NOTICE to Take Deposition of Nicole Twisk filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd..(Taylor, Daniel) (Entered: 10/19/2023) (3) |
| Oct 19, 2023 | 107 | NOTICE to Take Deposition of Novartis Pharmaceuticals Corporation Pursuant to Rule 30(b)(6) filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd..(Taylor, Daniel) (Entered: 10/19/2023) (4) |
| Sep 29, 2023 | 104 | REDACTED VERSION of 99 Letter, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 10/2/2023 (nms). (Entered: 09/29/2023) (30) |
| Sep 29, 2023 | 105 | REDACTED VERSION of 102 Letter, by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd.. (Attachments: # 1 Exhibits 1-10)(Taylor, Daniel) Modified on 10/2/2023 (nms). (Entered: 09/29/2023) (0) |
| Sep 25, 2023 | 103 | STIPULATION and Proposed Order to Extend Time - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 9/26/2023 (nms). (Entered: 09/25/2023) (4) |
| Sep 20, 2023 | 102 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel A. Taylor, regarding response in opposition to Plaintiff's motion to strike. (Attachments: # 1 Exhibits 1-10, # 2 Proposed Order, # 3 Certificate of Service)(Taylor, Daniel) Modified on 9/21/2023 (nms). (Entered: 09/20/2023) (0) |
| Sep 19, 2023 | 100 | NOTICE OF SERVICE of Novartis's Objections and Responses to Defendants' 2nd Set of Requests for Admission to Plaintiff Novartis Pharmaceuticals Corp. to Establish the Authenticity of Documents or to Establish Documents as Business Records filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 09/19/2023) (4) |
| Sep 19, 2023 | 101 | ORAL ORDER: Due to a scheduling conflict the Discovery Conference set for 9/27/2023, will now commence at 2:30 PM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 9/19/2023. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01760-RGA, 1:21-cv-01794-RGA, 1:22-cv-00451-RGA(nms) (Entered: 09/19/2023) (0) |
| Sep 18, 2023 | 99 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding opening expert report. (Attachments: # 1 Exhibits A-K, # 2 Proposed Order, # 3 Certificate of Service)(Silver, Daniel) Modified on 9/19/2023 (nms). (Entered: 09/18/2023) (0) |
| Sep 11, 2023 | 96 | NOTICE OF SERVICE of Expert Report of Stuart D. Katz Regarding Validity of U.S. Patent No. 11,058,667 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 09/11/2023) (4) |
| Sep 11, 2023 | 97 | NOTICE OF SERVICE of Defendants Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III, Mylan Pharmaceuticals Inc., Torrent Pharma Inc., and Torrent Pharmaceuticals Limited's Highly Confidential Responsive Expert Report of Dan Fintel, M.D. on noninfringement the '667 patent filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd..(Taylor, Daniel) (Entered: 09/11/2023) (2) |
| Sep 11, 2023 | 98 | NOTICE OF SERVICE of Defendants Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III, Mylan Pharmaceuticals Inc., Torrent Pharma Inc., and Torrent Pharmaceuticals Limited's Highly Confidential Responsive Expert Report of Jonathan W. Steed, Ph.D. on non-infringement of the '667 patent filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd..(Taylor, Daniel) (Entered: 09/11/2023) (2) |
| Aug 30, 2023 | 95 | ORAL ORDER: The parties have advised that a dispute has arisen requiring attention. The Court will hold a discovery conference on 9/27/2023, at 9:00 AM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 8/30/2023. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01760-RGA, 1:21-cv-01794-RGA, 1:22-cv-00451-RGA(nms) (Entered: 08/30/2023) (0) |
| Aug 18, 2023 | 94 | NOTICE OF SERVICE of Defendants Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III, Mylan Pharmaceuticals, Inc., Torrent Pharma Inc., and Torrent Pharmaceuticals Ltd.'s 2nd Set of Requests for Admissions (Nos. 1-5) to Plaintiff Novartis Pharmaceuticals Corporation to establish the authenticity of documents or establish documents as business records, regarding U.S. Patent No. 11,058,667 ("the '667 patent") filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd..(Belgam, Neal) (Entered: 08/18/2023) (2) |
| Jul 31, 2023 | 91 | NOTICE OF SERVICE of (1) Expert Report of Dr. Francis G. Spinale on the Infringement of the 667 Patent and (2) Opening Expert Report of Dr. Alexander M. Klibanov on the Infringement of the 667 Patent filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 07/31/2023) (5) |
| Jul 31, 2023 | 92 | NOTICE OF SERVICE of Novartis's Objections and Responses to Defendants' Requests for Admission to Plaintiff Novartis Pharmaceuticals Corporation to Establish the Authenticity of Documents or to Establish Documents as Business Records filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 07/31/2023) (4) |
| Jul 31, 2023 | 93 | NOTICE OF SERVICE of Opening Expert Report of Dan Fintel, M.D. on the Invalidity of U.S. Patent No. 11,058,667 [Highly Confidential-Outside Attorneys' Eyes Only] (also filed on behalf of the Hetero and Torrent Defendants) filed by Mylan Pharmaceuticals Inc..(Brown, Andrew) (Entered: 07/31/2023) (3) |
| Jul 12, 2023 | 90 | STIPULATION and Proposed Order to Extend Time regarding expert reports - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 7/12/2023 (nms). (Entered: 07/12/2023) (4) |
| Jul 5, 2023 | 89 | REDACTED VERSION of 86 Stipulation and Proposed Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/6/2023 (nms). (Entered: 07/05/2023) (4) |
| Jun 29, 2023 | 87 | [SEALED] ORDER Granting (D.I. 642 in 19-cv-1979-RGA; D.I. 171 in 21-cv-1330-RGA; D.I. 1086 in 20-md-2930-RGA; D.I. 86 in 21-cv-1794-RGA) Stipulation and Proposed Order. Signed by Judge Richard G. Andrews on 6/29/2023.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:21-cv-01330-RGA, 1:21-cv-01794-RGA(nms) (Entered: 06/29/2023) (0) |
| Jun 29, 2023 | 88 | MOTION for Pro Hac Vice Appearance of Attorney Melinda R. Roberts - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification for Melinda R. Roberts)(Silver, Daniel) (Entered: 06/29/2023) (Main Document) (4) |
| Jun 29, 2023 | 88 | MOTION for Pro Hac Vice Appearance of Attorney Melinda R. Roberts - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification for Melinda R. Roberts)(Silver, Daniel) (Entered: 06/29/2023) (Certification for Melinda R. Roberts) (1) |
| Jun 28, 2023 | 85 | NOTICE OF SERVICE of Defendants Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III, Mylan Pharmaceuticals, Inc., Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Requests for Admissions to Establish the Authenticity of Documents or Establish Documents as Business Records to Plaintiff Novartis Pharmaceuticals Corporation filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd..(Taylor, Daniel) (Entered: 06/28/2023) (2) |
| Jun 28, 2023 | 86 | [SEALED] STIPULATION and [Proposed] Order by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 06/28/2023) (0) |
| Jun 22, 2023 | 84 | NOTICE to Take Deposition of Nicole Twisk on June 30, 2023 filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd..(Palapura, Bindu) (Entered: 06/22/2023) (3) |
| Jun 20, 2023 | 83 | NOTICE to Take Deposition of Michael Motto on June 29, 2023 filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd..(Taylor, Daniel) (Entered: 06/20/2023) (3) |
| Jun 16, 2023 | 82 | NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendants' Third Set of Common Interrogatories (No. 14), and (2) Novartis's Second Supplemental Objections and Responses to Defendants' First Set of Common Interrogatories (Nos. 1-9) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/16/2023) (4) |
| Jun 15, 2023 | 81 | NOTICE OF SERVICE of Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Objections and Response to Plaintiff Novartis Pharmaceutical Corporation's Third Set of Interrogatories (Nos. 5-6) filed by Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Torrent Pharmaceuticals Ltd..(Taylor, Daniel) (Entered: 06/15/2023) (2) |
| Jun 14, 2023 | 79 | NOTICE to Take Deposition of Adel Remond Rizkala on June 16, 2023, filed by Mylan Pharmaceuticals Inc..(Moore, David) Modified on 6/14/2023 (nms). (Entered: 06/14/2023) (3) |
| Jun 14, 2023 | 80 | NOTICE to Take Deposition of Nicole Twisk, filed by Mylan Pharmaceuticals Inc..(Moore, David) Modified on 6/14/2023 (nms). (Entered: 06/14/2023) (3) |
| Jun 13, 2023 | 78 | NOTICE OF SERVICE of (1) Plaintiff's Supplemental Initial Paragraph 3 Disclosures Regarding Electronic Systems Information regarding the '667 Patent and (2) Plaintiff's Supplemental Rule 26 (A)(1) Initial Disclosures regarding the '667 Patent filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/13/2023) (4) |
| Jun 12, 2023 | 77 | NOTICE OF SERVICE of (1) Novartis Objections and Responses to Defendants Highly Confidential Attorneys Eyes Only First Set of Individual Requests for Admission to Plaintiff Novartis Pharmaceuticals Corporation (Nos. 1-10) (667 Patent), (2) Plaintiff's Objections and Responses to Defendants First Set of Individual Requests for Admissions (Nos. 1-8) (918 Patent), and (3) Plaintiff's Objections and Responses to Defendants' First Set of Requests for Admissions (Nos. 1-24) (918 Patent) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/12/2023) (5) |
| Jun 8, 2023 | 76 | NOTICE OF SERVICE of Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s (1) Objections and Responses to Novartis Pharmaceutical Corporation's Requests for Admissions to Establish Authenticity of Documents or Establish Documents as Business Records and (2) Objections and Responses to Novartis Pharmaceutical Corporation's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Torrent Pharmaceuticals Ltd..(Taylor, Daniel) (Entered: 06/08/2023) (2) |
| Jun 5, 2023 | 75 | NOTICE to Take Deposition of Peter Waibel on June 14, 2023 filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd..(Taylor, Daniel) (Entered: 06/05/2023) (3) |
| May 30, 2023 | 74 | NOTICE OF SERVICE of Responses and Objections to Novartis's Second Set of Common Interrogatories to Defendants filed by Mylan Pharmaceuticals Inc..(Brown, Andrew) (Entered: 05/30/2023) (3) |
| May 26, 2023 | 73 | NOTICE OF SERVICE of Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Highly Confidential Objections and Responses to Plaintiff Novartis Pharmaceutical Corporation's First Set of Requests for Admissions (Nos. 1-22) filed by Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Torrent Pharmaceuticals Ltd..(Taylor, Daniel) (Entered: 05/26/2023) (2) |
| May 22, 2023 | 72 | NOTICE OF SERVICE of Novartis Objections and Responses to Defendants' Notice of Deposition to Plaintiff Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/22/2023) (5) |
| May 19, 2023 | 71 | NOTICE OF SERVICE of Defendants' Joint Supplemental Invalidity Contentions for U.S. Patent No. 11,058,667 filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 05/19/2023) (3) |
| May 17, 2023 | 69 | NOTICE OF SERVICE of (1) Novartis's First Supplemental Objections and Responses to Defendants' First Set of Common Interrogatories (Nos. 1-9), (2) Novartis's Third Set of Interrogatories to Defendants (Nos. 5 & 6), and (3) Plaintiff Novartis's Supplemental Infringement Contentions Against Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/17/2023) (6) |
| May 17, 2023 | 70 | NOTICE OF SERVICE of Defendants' Third Set of Common Interrogatories (667 Patent) to Novartis (No. 14) filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 05/17/2023) (3) |
| May 11, 2023 | 68 | NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendants' Second Set of Common Interrogatories (Nos. 10-13), (2) Novartis's Objections and Responses to Defendants' Second Set of Joint Requests for the Production of Documents and Things (Nos. 45-56), (3) Novartis's Supplemental Infringement Contentions Against Crystal Pharmaceutical (Suzhou) Co., Ltd., and (4) Novartis's Objections and Responses to Crystal's First Set of Individual Interrogatories (Nos. 1-3) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/11/2023) (6) |
| May 10, 2023 | 67 | NOTICE OF SERVICE of Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Highly Confidential First Set of Individual Requests for Admission (Nos. 1-10) to Plaintiff Novartis Pharmaceutical Corporation filed by Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Torrent Pharmaceuticals Ltd..(Taylor, Daniel) (Entered: 05/10/2023) (2) |
| May 9, 2023 | 65 | NOTICE of Deposition Under Fed. R. Civ. P. 30(B)(6) to Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd. by Novartis Pharmaceuticals Corporation (Joyce, Alexandra) (Entered: 05/09/2023) (5) |
| May 9, 2023 | 66 | NOTICE OF SERVICE of Novartis's Requests for Admissions to Defendants to Establish the Authenticity of Documents or Establish Documents as Business Records filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/09/2023) (6) |
| May 5, 2023 | 60 | NOTICE to Take Deposition of Adel Remond Rizkala on at a date, time, and/or location to be determined filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 05/05/2023) (4) |
| May 5, 2023 | 61 | NOTICE to Take Deposition of Marcia Kayath on date, time, and/or location to be determined filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 05/05/2023) (4) |
| May 5, 2023 | 62 | NOTICE to Take Deposition of Victor Chengwei Shi on date, time, and/or location to be determined filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 05/05/2023) (4) |
| May 5, 2023 | 63 | NOTICE to Take Deposition of Fabian Chen on date, time, and/or location to be determined filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 05/05/2023) (4) |
| May 5, 2023 | 64 | NOTICE to Take Deposition of Plaintiff Novartis Pharmaceuticals Corporation on date, time, and/or location to be determined filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 05/05/2023) (12) |
| Apr 26, 2023 | 59 | NOTICE OF SERVICE of (1) Novartis's Second Set of Common Interrogatories to Defendants and (2) Novartis's First Set of Requests for Admissions to Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 04/26/2023) (6) |
| Apr 25, 2023 | 58 | NOTICE OF SERVICE of Torrent Defendants' First Supplemental Objections & Responses to Novartis's First Set of Interrogatories filed by Torrent Pharma Inc., Torrent Pharmaceticals Ltd..(Taylor, Daniel) (Entered: 04/25/2023) (2) |
| Apr 14, 2023 | 57 | NOTICE of Appearance by Daniel Taylor on behalf of Torrent Pharma Inc., Torrent Pharmaceticals Ltd. (Taylor, Daniel) (Entered: 04/14/2023) (2) |
| Apr 12, 2023 | 56 | ORAL ORDER: The agreed-upon constructius (see D.I. 66 in 22-cv-451-RGA; D.I. 56 in 21-cv-1452-RGA; D.I. 58 in 22-cv-498-RGA; D.I. 989 in 20-md-2930-RGA; D.I. 56 in 21-cv-1760-RGA; D.I. 55 in 21-cv-1794-RGA) are ACCEPTED. The Markman hearing scheduled for 4/14/2023, is CANCELED. Ordered by Judge Richard G. Andrews on 4/12/2023. Associated Cases: 1:20-md-02930-RGA et al.(nms) (Entered: 04/12/2023) (0) |
| Apr 11, 2023 | 54 | NOTICE OF SERVICE of copies of (i) Defendants' Second Set of Common Interrogatories to Novartis (Nos. 10-13); and, (ii) Defendants' Second Set of Joint Requests for the Production of Documents and Things (Nos. 45-56) to Novartis filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 04/11/2023) (3) |
| Apr 11, 2023 | 55 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding Markman hearing scheduled for 4/14/2023, regarding U.S. Patent No. 11,058,667. (Silver, Daniel) Modified on 4/12/2023 (nms). (Entered: 04/11/2023) (2) |
| Apr 7, 2023 | 53 | REDACTED VERSION of 49 Appendix, Volume 2, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 4/7/2023 (nms). (Entered: 04/07/2023) (20) |
| Apr 5, 2023 | 52 | MARKMAN HEARING ORDER: The Joint Claim Construction Brief (D.I. 974 ) is UNSEALED. The argument at the Markman Hearing on April 14, 2023, is limited to ten minutes per side. For the first disputed term, there appears to be a definition at '667 Patent 16:20-24. I think that is what each side means by their proposals. In any event, the parties' proposals are STRUCK. If either party thinks the above-referenced definition is inadequate in some regard, that party is to propose a construction including the definition and any additional language that the party argues is necessary. "Specific," as already proposed by Defendants, is rejected. I note that "crystalline," as proposed by Defendants, seems to be agreed upon by Novartis. (D.I. 974 at 31). But I am unclear whether it is necessary. Any proposed constructions should be submitted by 5 p.m. Tuesday, April 11, 2023. The proposed construction and any justification for it shall be set forth in 250 words or less. For the second disputed term, there also appears to be a definition, this time at '667 Patent 5:22-35. The parties only have one disagreement (in addition to the one addressed above in 3), which is Defendants' proposed negative limitation. As I understand Novartis's position, there is no dispute because part (a) of the definition includes exactly one "complex"-the one described at '667 Patent 16:20-24-and part (b) includes no complexes at all. If Novartis confirms that I understand its position correctly, then I also agree with Novartis that adding a negative limitation is pointless. Novartis should advise whether it confirms the above no later than 5 p.m. Tuesday, April 11, 2023. Signed by Judge Richard G. Andrews on 4/5/2023. Associated Cases: 1:20-md-02930-RGA et al.(nms) (Entered: 04/05/2023) (2) |
| Mar 31, 2023 | 47 | Joint Claim Construction Brief regarding U.S. Patent No. 11,058,667, filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 3/31/2023 (nms). Modified on 4/5/2023 (nms). (Entered: 03/31/2023) (30) |
| Mar 31, 2023 | 48 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Main Document) (5) |
| Mar 31, 2023 | 49 | [SEALED] APPENDIX, Volume 2 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits L-N)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (0) |
| Mar 31, 2023 | 50 | APPENDIX, Volume 3 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits O-V)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Main Document) (5) |
| Mar 31, 2023 | 51 | Joint Motion for Claim Construction - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 4/3/2023 (nms). (Entered: 03/31/2023) (8) |
| Mar 31, 2023 | 50 | APPENDIX, Volume 3 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits O-V)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit O-V) (30) |
| Mar 31, 2023 | 48 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 1) (16) |
| Mar 31, 2023 | 48 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 2 Pt. 1 of 5) (30) |
| Mar 31, 2023 | 48 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 2 Pt. 2 of 5) (30) |
| Mar 31, 2023 | 48 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 2 Pt. 3 of 5) (30) |
| Mar 31, 2023 | 48 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 2 Pt. 4 of 5) (30) |
| Mar 31, 2023 | 48 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit 2 Pt. 5 of 5) (13) |
| Mar 31, 2023 | 48 | APPENDIX, Volume 1 to Joint Claim Construction Brief, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 part 1, # 3 Exhibit 2 part 2, # 4 Exhibit 2 part 3, # 5 Exhibit 2 part 4, # 6 Exhibit 2 part 5, # 7 Exhibits A-K)(Joyce, Alexandra) Modified on 3/31/2023 (nms). (Entered: 03/31/2023) (Exhibit A-K) (30) |
| Mar 24, 2023 | 46 | NOTICE OF SERVICE of (i) Defendants' Sur-Reply Brief on Claim Construction for U.S. Patent No. 11,058,667 with Exs. U and V [HIGHLY CONFIDENTIAL-ATTORNEYS EYES ONLY]; and, (ii) a replacement version of Ex. H, which was previously served on February 10, 2023 with Defendants' Responsive Brief on Claim Construction for U.S. Patent No. 11,058,667 filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 03/24/2023) (3) |
| Mar 22, 2023 | 45 | NOTICE of Change of Address by Alexandra M. Joyce (Joyce, Alexandra) (Entered: 03/22/2023) (5) |
| Mar 17, 2023 | 44 | NOTICE of Withdrawal of Appearance of Delaware Counsel, Eve Ormerod by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Hetero USA Inc., (Ormerod, Eve) (Entered: 03/17/2023) (3) |
| Mar 6, 2023 | 42 | NOTICE OF SERVICE of Defendants' Objections and Responses to Novartis's First Set of Common Interrogatories (No. 1) filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 03/06/2023) (5) |
| Mar 6, 2023 | 43 | NOTICE OF SERVICE of Novartis's Reply Brief on Claim Construction for U.S. Patent No. 11,058,667 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 03/06/2023) (7) |
| Feb 10, 2023 | 41 | NOTICE OF SERVICE of Defendants' Responsive Brief on Claim Construction for U.S. Patent No. 11,058,667 [HIGHLY CONFIDENTIAL] filed by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Gattuso, Dominick) (Entered: 02/10/2023) (3) |
| Feb 2, 2023 | 40 | NOTICE OF SERVICE of Novartis's First Set of Common Interrogatories to Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 02/02/2023) (7) |
| Jan 23, 2023 | 39 | NOTICE OF SERVICE of Novartis's Opening Brief on Claim Construction for U.S. Patent No. 11,058,667 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 01/23/2023) (7) |
| Jan 11, 2023 | 38 | NOTICE OF SERVICE of Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s First Supplemental Response and Objections to Plaintiff's Second Set of Interrogatories (No. 5) filed by Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) (Entered: 01/11/2023) (1) |
| Dec 30, 2022 | 37 | JOINT Claim Construction Chart for U.S. Patent No. 11,058,667, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Appendix)(Silver, Daniel) Modified on 1/2/2023 (nms). (Entered: 12/30/2022) (Main Document) (13) |
| Dec 30, 2022 | 37 | JOINT Claim Construction Chart for U.S. Patent No. 11,058,667, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Appendix)(Silver, Daniel) Modified on 1/2/2023 (nms). (Entered: 12/30/2022) (Appendix) (30) |
| Dec 15, 2022 | 35 | NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendants' First Set of Joint Requests for Production (Nos. 1-44) for the '667 patent, and (2) Novartis's Objections and Responses to Defendants' First Set of Common Interrogatories (Nos. 1-9) for the '667 patent filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 12/15/2022) (7) |
| Dec 15, 2022 | 36 | NOTICE OF SERVICE of Novartis's Rebuttal Proposed Constructions of Claim Terms and Evidence for U.S. Patent No. 11,058,667 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 12/15/2022) (7) |
| Dec 6, 2022 | 34 | STIPULATION TO EXTEND TIME the Deadline to Substantially Complete Document Production to January 18, 2023 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 12/06/2022) (7) |
| Nov 8, 2022 | 33 | NOTICE OF SERVICE of Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.s Objections and Responses to Novartis Second set of Interrogatories (Nos. 4-5) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) (Entered: 11/08/2022) (2) |
| Oct 7, 2022 | 32 | NOTICE OF SERVICE of Novartis's Second Set of Interrogatories to Defendants filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 10/07/2022) (10) |
| Sep 9, 2022 | 31 | NOTICE OF SERVICE of Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Objections and Responses to Plaintiff Novartis Pharmaceutical Corporations First Set of Interrogatories and First Set of Requests for the Production of Documents and Things filed by Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) (Entered: 09/09/2022) (2) |
| Sep 7, 2022 | 29 | NOTICE OF SERVICE of Defendants Torrent Pharma, Inc. and Torrent Pharmaceuticals, Ltd.'s Rule 26(a) Initial Disclosures and Paragraph 3 Disclosures filed by Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) (Entered: 09/07/2022) (2) |
| Sep 7, 2022 | 30 | NOTICE OF SERVICE of (1) Plaintiff's Rule 26(a)(1) Initial Disclosures, and (2) Plaintiff's Initial Paragraph 3 Disclosures Regarding Electronic Systems Information filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 09/07/2022) (14) |
| Aug 29, 2022 | 28 | SCHEDULING ORDER: Joinder of Parties due by 1/5/2023. Amended Pleadings due by 1/5/2023. Fact Discovery completed by 6/16/2023. Joint Claim Construction Brief due by 3/31/2023. A Markman Hearing is set for 4/14/2023, at 9:00 AM in Courtroom 6A. A Pretrial Conference is set for 2/2/2024, at 9:00 AM in Courtroom 6A. A 7 day Bench Trial is set to start 2/12/2024, at 8:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 8/29/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) (Entered: 08/29/2022) (21) |
| Aug 26, 2022 | 27 | PROPOSED Scheduling Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/28/2022 (nms). (Entered: 08/26/2022) (21) |
| Aug 17, 2022 | 26 | Official Transcript of Rule 16 Conference held on 8/3/22 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 9/7/2022. Redacted Transcript Deadline set for 9/19/2022. Release of Transcript Restriction set for 11/15/2022. (Triozzi, Heather) (Entered: 08/17/2022) (29) |
| Aug 11, 2022 | 25 | NOTICE OF SERVICE of (1) Novartis's First Set of Requests to Defendants for the Production of Documents and Things and (2) Novartis's First Set of Interrogatories to Defendants (Nos. 1-3) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 08/11/2022) (13) |
| Aug 3, 2022 | N/A | Scheduling Conference (0) Docket Text: Minute Entry for proceedings held before Judge Richard G. Andrews - Scheduling Conference held on 8/3/2022. Counsel for Plaintiff: D. Silver. Counsel for Defendants: E. Ormerod, A. Poff, R. Weinblatt, C. Hitch, D. Gattuso, B. Palapura, J. Seaman. Plaintiff is directed to submit the revised order. (Court Reporter Heather Triozzi.) Associated Cases: 1:22-cv-00032-RGA et al.(lak) |
| Jul 25, 2022 | 24 | Notice of Service (16) Docket Text: NOTICE OF SERVICE of Plaintiff's Initial Infringement Chart for U.S. Patent No. 11,058,667 and Plaintiff's First Supplemental Infringement Chart for U.S. Patent No. 11,096,918 against Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Jul 21, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: A Scheduling Conference is now set for 8/3/2022, at 2:00 PM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 7/21/2022. Associated Cases: 1:22-cv-00032-RGA et al.(nms) |
| Jun 15, 2022 | 22 | Proposed Order (21) Docket Text: PROPOSED Scheduling Order (with disputed provisions), by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/15/2022 (nms). |
| Jun 13, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order Extending Time to submit a Proposed Scheduling Order to June 15, 2022. Signed by Judge Richard G. Andrews on 6/13/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Jun 10, 2022 | 21 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION and Proposed Order Extending Time to submit Proposed Scheduling Order to June 15, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/13/2022 (nms). |
| Jun 9, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order to June 10, 2022. Signed by Judge Richard G. Andrews on 6/9/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Jun 9, 2022 | 20 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for parties to submit a Proposed Scheduling Order to June 10, 2022 - filed by Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd.. (Ormerod, Eve) |
| Jun 2, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to June 8, 2022. Signed by Judge Richard G. Andrews on 6/2/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Jun 1, 2022 | 18 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME the parties' deadline to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 in accordance with the Court's oral order at the April 21, 2022 status conference to June 8, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| May 26, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to and including June 1, 2022. Signed by Judge Richard G. Andrews on 5/26/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 25, 2022 | 17 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 in accordance with the Court's oral order at the April 21, 2022 status conference to June 1, 2022 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 19, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to May 25, 2022. Signed by Judge Richard G. Andrews on 5/19/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 18, 2022 | 16 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME deadline to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to May 25, 2022. - filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) |
| May 11, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order to May 18, 2022. Signed by Judge Richard G. Andrews on 5/11/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 11, 2022 | 15 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for parties to submit a Proposed Scheduling Order to May 18, 2022 - filed by Torrent Pharma Inc., Torrent Pharmaceticals Ltd.. (Ormerod, Eve) |
| May 5, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to May 11, 2022. Signed by Judge Richard G. Andrews on 5/5/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 4, 2022 | 14 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 in accordance with the Court's oral order at the April 21, 2022 status conference to May 11, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Apr 7, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:21-cv-01330-LPS et al. (ntl) |
| Apr 5, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Christopher E. Loh for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Apr 1, 2022 | 13 | Status Report (9) Docket Text: Joint STATUS REPORT by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Mar 29, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Leonard P. Stark of the United States Court of Appeals for the Federal Circuit. Please include the initials of the Judge (LPS) after the case number on all documents filed. Associated Cases: 1:18-cv-01038-LPS et al. (ntl) |
| Mar 29, 2022 | N/A | Order (0) Docket Text: ORAL ORDER: The Court observes that this case is marked as related to one or more other cases now pending before another judge of this Court. Accordingly, IT IS HEREBY ORDERED that the parties shall meet and confer and, no later than April 1, submit a joint status report, providing their position(s) as to which judge this case should be reassigned to. ORDERED by Judge Leonard P. Stark on 3/29/22. (ntl) |
| Mar 17, 2022 | 10 | Main Document (2) Docket Text: DECLARATION of Service of Torrent Pharmaceuticals Ltd., by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibits A-B)(Joyce, Alexandra) Modified on 4/8/2022 (nms). |
| Mar 17, 2022 | 10 | Exhibit A-B (7) |
| Mar 17, 2022 | 11 | Summons Returned Executed (3) Docket Text: SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. Torrent Pharma Inc. served on 3/10/2022, answer due 3/31/2022. (Joyce, Alexandra) |
| Mar 15, 2022 | N/A | Create Case Association (0) Docket Text: Case associated with lead case: Create association to 1:20-md-02930-RGA. (ntl) |
| Jan 11, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (9 in 1:21-cv-01760-LPS, 9 in 1:21-cv-01794-LPS) MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, Susanne L. Flanders, Jared L. Stringham, Shannon K. Clark, Laura K. Fishwick, Gregory J. Manas filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 1/11/22. Associated Cases: 1:21-cv-01794-LPS, 1:21-cv-01760-LPS (ntl) |
| Jan 11, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Shannon K. Clark,Nicholas N. Kallas,Jared L. Stringham,Christina Schwarz,Laura K. Fishwick for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:21-cv-01794-LPS, 1:21-cv-01760-LPS, 1:21-cv-01797-LPS(mal) |
| Jan 10, 2022 | 9 | Main Document (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, Susanne L. Flanders, Jared L. Stringham, Shannon K. Clark, Laura K. Fishwick, Gregory J. Manas - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, Susanne L. Flanders, Jared L. Stringham, Shannon K. Clark, Laura K. Fishwick, Gregory J. Manas)(Silver, Daniel) |
| Jan 10, 2022 | 9 | Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, S (8) |
| Jan 7, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Dmitry V. Shelhoff, Julia S. Kim, Edward D. Pergament and Kenneth S. Canfield for Torrent Pharma Inc. and Torrent Pharmaceticals Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mal) |
| Jan 5, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [8] MOTION for Pro Hac Vice Appearance of Attorney Dmitry V. Shelhoff, Edward D. Pergament, Kenneth S. Canfield, Julia S. Kim filed by Torrent Pharmaceticals Ltd., Torrent Pharma Inc. Signed by Judge Leonard P. Stark on 1/5/22. (ntl) |
| Jan 4, 2022 | 6 | Answer to Complaint (8) Docket Text: ANSWER to [1] Complaint and Additional Defenses, by Torrent Pharma Inc., Torrent Pharmaceticals Ltd..(Ormerod, Eve) Modified on 4/8/2022 (nms). |
| Jan 4, 2022 | 7 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Torrent Pharma Inc., Torrent Pharmaceticals Ltd.. (Ormerod, Eve) |
| Jan 4, 2022 | 8 | Motion for Leave to Appear Pro Hac Vice (6) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Dmitry V. Shelhoff, Edward D. Pergament, Kenneth S. Canfield, Julia S. Kim - filed by Torrent Pharma Inc., Torrent Pharmaceticals Ltd.. (Belgam, Neal) |
| Dec 29, 2021 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. (rjb) |
| Dec 22, 2021 | N/A | No Summons Issued (0) Docket Text: No Summons Issued. (mal) |
| Dec 22, 2021 | 1 | Main Document (12) Docket Text: COMPLAINT filed against Torrent Pharma Inc., Torrent Pharmaceticals Ltd. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3769067.) - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A, # (2) Civil Cover Sheet)(mal) |
| Dec 22, 2021 | 1 | Exhibit A (16) |
| Dec 22, 2021 | 1 | Civil Cover Sheet (2) |
| Dec 22, 2021 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mal) |
| Dec 22, 2021 | 3 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No Earlier than 11/11/2021. Date of Expiration of Patent: 05/09/2036. 30 Month Stay Deadline: see attached. (mal) |
| Dec 22, 2021 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,058,667. (mal) |
| Dec 22, 2021 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (mal) |
| Dec 22, 2021 | 1 | Complaint* (1) |
